Initiator Pharma A/S (OSTO:INIT) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Initiator Pharma A/S Debt-to-Equity?

Initiator Pharma A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Initiator Pharma A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Initiator Pharma A/S's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr35.97 Mil. Initiator Pharma A/S's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Initiator Pharma A/S's Debt-to-Equity or its related term are showing as below:

OSTO:INIT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.33 Med: 0.51 Max: 1.6
Current: 0.64

During the past 8 years, the highest Debt-to-Equity Ratio of Initiator Pharma A/S was 1.60. The lowest was 0.33. And the median was 0.51.

OSTO:INIT's Debt-to-Equity is ranked worse than
78.63% of 1062 companies
in the Biotechnology industry
Industry Median: 0.145 vs OSTO:INIT: 0.64

Initiator Pharma A/S Debt-to-Equity Historical Data

The historical data trend for Initiator Pharma A/S's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Initiator Pharma A/S Debt-to-Equity Chart

Initiator Pharma A/S Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.38

0.37

1.38

Initiator Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.51	0.90	1.60	1.38	-

Competitive Comparison of Initiator Pharma A/S's Debt-to-Equity

For the Biotechnology subindustry, Initiator Pharma A/S's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Initiator Pharma A/S's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Initiator Pharma A/S's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Initiator Pharma A/S's Debt-to-Equity falls into.

Initiator Pharma A/S Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Initiator Pharma A/S's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	23.168)	/	16.752
	=	1.38

Initiator Pharma A/S's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	35.973
	=	0.00

Initiator Pharma A/S (OSTO:INIT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Initiator Pharma A/S Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Initiator Pharma A/S's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Initiator Pharma A/S (OSTO:INIT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Initiator Pharma A/S (OSTO:INIT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Co/ COBIS, Ole Maaloesvej 3, Copenhagen, DNK, 2200

Website

https://www.initiatorpharma.com

Initiator Pharma A/S is a clinical Stage Life Science company engaged in the research and development of various drugs targeting medical needs within the central and peripheral nervous system. The company's principal drug candidate is the IPED2015, a type of monoamine reuptake inhibitor (MRI) that has completed preclinical development for the treatment of erectile dysfunction in men. Its MRI drug candidates also include IPDP2015 for the treatment of depression; and IPNP2015 to treat neuropathic pain.

Initiator Pharma A/S (OSTO:INIT) Headlines

No Headlines